S. A. Abdalla, C. J. Gallione, R. J. Barst, E. M. Horn, J. A. Knowles et al., Primary Pulmonary Hypertension in Families with Hereditary Haemorrhagic Telangiectasia, vol.23, pp.373-77, 2004.

H. Al-samkari, A. Kritharis, J. M. Rodriguez-lopez, and D. J. Kuter, « Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Haemorrhagic Telangiectasia, Journal of Internal Medicine, vol.285, issue.2, pp.223-254, 2019.

F. Antigny, A. Hautefort, J. Meloche, M. Belacel-ouari, B. Manoury et al., KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension, Potassium Channel Subfamily K Member, vol.3, issue.14, pp.1371-85

D. S. Ardelean, M. Et, and . Letarte, Anti-Angiogenic Therapeutic Strategies in Hereditary Hemorrhagic Telangiectasia, vol.6, p.35, 2015.

H. M. Arthur, J. Ure, A. J. Smith, G. Renforth, D. I. Wilson et al., « Endoglin, an Ancillary TGFbeta Receptor, Is Required for Extraembryonic Angiogenesis and Plays a Key Role in Heart Development, Developmental Biology, vol.217, issue.1, pp.42-53, 2000.

T. Asaki, K. Kuwano, K. Morrison, J. Gatfield, T. Hamamoto et al., An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension, Journal of Medicinal Chemistry, vol.58, issue.18, pp.7128-7165

J. L. Babitt, Y. Zhang, T. A. Samad, Y. Xia, J. Tang et al., « Repulsive Guidance Molecule (RGMa), a DRAGON Homologue, Is a Bone Morphogenetic Protein Co-Receptor », The Journal of Biological Chemistry, vol.280, pp.29820-29847


M. Barratt, D. Frail, and . Repositioning, Bringing New Life to Shelved Assets and Existing Drugs. ». ChemMedChem, vol.8, issue.2, pp.336-373, 2013.

C. Barette, E. Soleilhac, C. Charavay, C. Cochet, M. Et et al., Strength and specificity of the CMBA screening platform for bioactive molecules discovery] ». Medecine Sciences: M/S 31, pp.423-454, 2015.

R. J. Barst, L. J. Rubin, W. A. Long, M. D. Mcgoon, S. Rich et al., « A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension, The New England Journal of Medicine, vol.334, issue.5, pp.296-301, 1996.

H. Beppu, F. Ichinose, N. Kawai, R. C. Jones, P. B. Yu et al., « BMPR-II Heterozygous Mice Have Mild Pulmonary Hypertension and an Impaired Pulmonary Vascular Remodeling Response to Prolonged Hypoxia, American Journal of Physiology. Lung Cellular and Molecular Physiology, vol.287, issue.6, pp.1241-1247, 2004.

M. Bidart, N. Ricard, S. Levet, M. Samson, C. Mallet et al., « BMP9 Is Produced by Hepatocytes and Circulates Mainly in an Active Mature Form Complexed to Its Prodomain ». Cellular and Molecular Life Sciences: CMLS 69, pp.313-337, 2012.

J. A. Bittker, High-Throughput RT-PCR for Small-Molecule Screening Assays

A. Bourdeau, D. J. Dumont, and M. Letarte, « A Murine Model of Hereditary Hemorrhagic Telangiectasia, The Journal of Clinical Investigation, vol.104, issue.10, pp.1343-51, 1999.

G. D. Bowden, M. Kirkwood, R. M. Land, H. M. O'connor, and . Fritz, « Highthroughput screen of drug repurposing library identifies inhibitors of Sarcocystis neurona growth, International Journal for Parasitology: Drugs and Drug Resistance, vol.8, issue.1, pp.137-181, 2018.

B. Bragdon, O. Moseychuk, S. Saldanha, D. King, J. Julian et al., Bone Morphogenetic Proteins: A Critical Review, vol.23, pp.609-629, 2011.

D. P. Brazil, H. Rachel, S. Church, and . Surae, Catherine Godson, et Finian Martin. « BMP Signalling: Agony and Antagony in the Family », Trends in Cell Biology, vol.25, issue.5, pp.249-64, 2015.

B. T. Brinkerhoff, W. Nicholas, J. S. Choong, D. M. Treisman, and . Poetker, Intravenous and Topical Intranasal Bevacizumab (Avastin) in Hereditary Hemorrhagic Telangiectasia, vol.33, pp.349-51, 2012.

M. A. Brown, Q. Zhao, K. A. Baker, C. Naik, C. Chen et al., « Crystal Structure of BMP-9 and Functional Interactions with pro-Region and Receptors, The Journal of Biological Chemistry, vol.280, pp.25111-25129

G. Brunet, G. Lesca, E. Génin, S. Dupuis-girod, A. Bideau et al., « Trente ans d'étude de la maladie de Rendu-Osler en France : démographie historique, génétique des populations et biologie moléculaire, vol.64, pp.305-330, 2009.

J. Cai, E. Pardali, G. Sánchez-duffhues, and E. Peter-ten-dijke, BMP Signaling in Vascular Diseases, vol.586, pp.1993-2002

. Castonguay, E. D. Roselyne, R. G. Werner, E. Matthews, A. W. Presman et al., Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth, The Journal of Biological Chemistry, vol.286, pp.30034-30080

A. J. Celeste, J. A. Iannazzi, R. C. Taylor, R. M. Hewick, V. Rosen et al., « Identification of Transforming Growth Factor Beta Family Members Present in Bone-Inductive Protein Purified from Bovine Bone, Proceedings of the National Academy of Sciences of the United States of America, vol.87, pp.9843-9890, 1990.

. Chen, H. Chih-hsuan, R. Hsu, P. Hu, C. Lee et al., Long-Term Therapy with Thalidomide in Hereditary Hemorrhagic Telangiectasia: Case Report and Literature Review, vol.52, pp.1436-1476, 2012.

H. Chen, S. Shi, L. Acosta, W. Li, J. Lu et al., « BMP10 Is Essential for Maintaining Cardiac Growth during Murine Cardiogenesis, vol.131, pp.2219-2250, 2004.


. Chen, J. B. Hao, T. Ridgway, J. Sai, S. Lai et al., « Context-Dependent Signaling Defines Roles of BMP9 and BMP10 in Embryonic and Postnatal Development, Proceedings of the National Academy of Sciences of the United States of America, vol.110, pp.11887-92

X. Chen, A. Zankl, F. Niroomand, Z. Liu, H. A. Katus et al., « Upregulation of ID Protein by Growth and Differentiation Factor 5 (GDF5) through a Smad-Dependent and MAPK-Independent Pathway in HUVSMC, Journal of Molecular and Cellular Cardiology, vol.41, issue.1, pp.26-33, 2006.

E. R. Chilvers, M. K. Whyte, J. E. Jackson, D. J. Allison, and J. M. Hughes, « Effect of Percutaneous Transcatheter Embolization on Pulmonary Function, Right-to-Left Shunt, and Arterial Oxygenation in Patients with Pulmonary Arteriovenous Malformations ». The American Review of Respiratory Disease 142, pp.420-445, 1990.


R. A. Coleman, W. L. Smith, and S. Narumiya, International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes, vol.46, pp.205-234

. Colombo, Realdo (1510?-1559) Auteur du texte. De re anatomica libri XV, p.1559

N. P. Coussens, C. John, T. Braisted, . Peryea, A. Sitta-sittampalam et al., « Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs, Pharmacological reviews, vol.69, issue.4, pp.479-96, 2017.

S. I. Cunha, E. Pardali, M. Thorikay, C. Anderberg, L. Hawinkels et al., Peter ten Dijke, et Kristian Pietras. « Genetic and Pharmacological Targeting of Activin Receptor-like Kinase 1 Impairs Tumor Growth and Angiogenesis, vol.207, pp.85-100

L. David, J. Feige, S. Et, and . Bailly, « Emerging Role of Bone Morphogenetic Proteins in Angiogenesis, Cytokine & Growth Factor Reviews, vol.20, issue.3, pp.203-215, 2009.

L. David, C. Mallet, M. Keramidas, N. Lamandé, J. Gasc et al., Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence Factor, vol.102, pp.914-936
URL : https://hal.archives-ouvertes.fr/inserm-00277236

L. David, C. Mallet, S. Mazerbourg, J. Feige, S. Et et al., « Identification of BMP9 and BMP10 as Functional Activators of the Orphan Activin Receptorlike Kinase 1 (ALK1) in Endothelial Cells, Blood, vol.109, issue.5, pp.1953-61

. Davie, S. J. Neil, P. D. Haleen, J. M. Upton, . Polak et al.,

J. Morrell, . «. Wharton, and . Et, A) and ET(B) Receptors Modulate the Proliferation of Human Pulmonary Artery Smooth Muscle Cells, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.3, pp.398-405, 2002.

. Deng, J. H. Zemin, S. L. Morse, N. Slager, K. J. Cuervo et al., « Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor-II Gene, American Journal of Human Genetics, vol.67, issue.3, pp.737-781, 2000.

R. Derynck and Y. E. Zhang, « Smad-Dependent and Smad-Independent Pathways in TGF-Beta Family Signalling », Nature, vol.425, pp.577-84, 2003.

A. Dompmartin, M. Vikkula, and L. M. Boon, « Venous Malformation: Update on Aetiopathogenesis, Diagnosis and Management, Phlebology, vol.25, issue.5, pp.224-259, 2010.

B. J. Dunmore, K. M. Drake, P. D. Upton, M. R. Toshner, M. A. Aldred et al., The Lysosomal Inhibitor, Chloroquine, Increases Cell Surface BMPR-II Levels and Restores BMP9 Signalling in Endothelial Cells Harbouring BMPR-II Mutations, vol.22, pp.3667-79

S. Dupuis-girod, A. Chesnais, I. Ginon, J. Dumortier, J. Saurin et al., Long-Term Outcome of Patients with Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Involvement after Orthotopic Liver Transplantation: A Single-Center Study ». Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol.16, pp.340-387, 2010.

S. Dupuis-girod, I. Ginon, J. Saurin, D. Marion, E. Guillot et al., Adeline Roux, et al. « Bevacizumab in Patients with Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output, JAMA, vol.307, issue.9, pp.948-55

J. A. Dutton, J. E. Jackson, J. M. Hughes, M. K. Whyte, A. M. Peters et al., « Pulmonary Arteriovenous Malformations: Results of Treatment with Coil Embolization, p.53

». A. Patients, American Journal of Roentgenology, vol.165, issue.5, pp.1119-1144, 1995.

T. Ebisawa, K. Tada, I. Kitajima, K. Tojo, T. K. Sampath et al., « Characterization of Bone Morphogenetic Protein-6 Signaling Pathways in Osteoblast Differentiation », Journal of Cell Science, vol.112, pp.3519-3546

. Eerola, L. M. Iiro, J. B. Boon, P. E. Mulliken, A. Burrows et al., Romain Vanwijck, et Miikka Vikkula. « Capillary Malformation-Arteriovenous Malformation, a New Clinical and Genetic Disorder Caused by RASA1 Mutations, American Journal of Human Genetics, vol.73, issue.6, pp.1240-1289, 2003.


M. Elvers, A. Herrmann, P. Seizer, P. Münzer, S. Beck et al., Intracellular cyclophilin A is an important Ca 2+ regulator in platelets and critically involved in arterial thrombus formation, Blood, vol.120, issue.6, p.1317, 2012.

N. Epperla and W. Hocking, « Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia, Clinical Medicine & Research, vol.13, issue.1, pp.32-35, 2015.

M. E. Faughnan, V. A. Palda, G. Garcia-tsao, U. W. Geisthoff, J. Mcdonald et al., « International Guidelines for the Diagnosis and Management of Hereditary Haemorrhagic Telangiectasia, Journal of Medical Genetics, vol.48, issue.2, pp.73-87, 2011.

M. E. Faughnan, R. James, M. M. Gossage, S. P. Chakinala, R. Oh et al., Pazopanib May Reduce Bleeding in Hereditary Hemorrhagic Telangiectasia, vol.22, pp.145-55, 2019.

J. M. Fleagle, K. Ravi, C. G. Bobba, C. E. Kardinal, and . Freter, « Iron Deficiency Anemia Related to Hereditary Hemorrhagic Telangiectasia: Response to Treatment with Bevacizumab, The American Journal of the Medical Sciences, vol.343, issue.3, pp.249-51, 2012.

D. Flieger, S. Hainke, W. Et, and . Fischbach, « Dramatic Improvement in Hereditary Hemorrhagic Telangiectasia after Treatment with the Vascular Endothelial Growth Factor (VEGF) Antagonist Bevacizumab », Annals of Hematology, vol.85, issue.9, pp.631-663, 2006.

P. Fodstad, S. Dheyauldeen, M. Rinde, and G. Bachmann-harildstad, Anti-VEGF with 3-Week Intervals Is Effective on Anemia in a Patient with Severe Hereditary Hemorrhagic Telangiectasia, vol.90, pp.611-623, 2011.

S. Föllner, M. Ibe, J. Et, and . Schreiber, Bevacizumab Treatment in Hereditary Hemorrhagic Teleangiectasia, vol.68, pp.1685-86, 2012.

M. Franchini, F. Frattini, S. Crestani, C. Et, and . Bonfanti, « Novel Treatments for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review of the Clinical Experience with Thalidomide, Journal of Thrombosis and Thrombolysis, vol.36, issue.3, pp.355-57, 2013.

M. Fruttiger, « Development of the Retinal Vasculature, Angiogenesis, vol.10, issue.2, pp.77-88, 2007.

M. Fujiwara, H. Yagi, R. Matsuoka, K. Akimoto, M. Furutani et al., Implications of Mutations of Activin Receptor-like Kinase, vol.1

, Addition to Bone Morphogenetic Protein Receptor II Gene (BMPR2) in Children with Pulmonary Arterial Hypertension, Circulation Journal: Official Journal of the Japanese Circulation Society, vol.72, issue.ALK1, pp.127-160, 2008.

S. Gaillard, S. Dupuis-girod, F. Boutitie, S. Rivière, S. Morinière et al., Tranexamic Acid for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients: A European Cross-over Controlled Trial in a Rare Disease, Journal of Thrombosis and Haemostasis: JTH, vol.12, issue.9, pp.1494-1502, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02071525

D. S. Jong, W. T. De, J. M. Steegenga, E. J. Hendriks, W. Van-zoelen et al., « Regulation of Notch Signaling Genes during BMP2-Induced Differentiation of Osteoblast Precursor Cells, Biochemical and Biophysical Research Communications, vol.320, issue.1, pp.100-107

D. S. Jong, B. L. De, K. J. Vaes, A. Dechering, . Feijen et al., Identification of Novel Regulators Associated with Early-Phase Osteoblast Differentiation, vol.19, pp.947-58, 2004.

F. S. Govani, C. L. Et, and . Shovlin, « Hereditary Haemorrhagic Telangiectasia: A Clinical and Scientific Review, European Journal of Human Genetics: EJHG, vol.17, issue.7, pp.860-71, 2009.

T. Grewal, R. Evans, C. Rentero, F. Tebar, L. Cubells et al., « Annexin A6 Stimulates the Membrane Recruitment of P120GAP to Modulate Ras and Raf-1 Activity, Oncogene, vol.24, pp.5809-5829

C. Guignabert, L. Tu, B. Girerd, N. Ricard, A. Huertas et al., « New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension: Importance of Endothelial Communication, vol.147, pp.529-566, 2015.

P. Gupta, C. Mordin, J. Curtis, J. M. Hughes, C. L. Shovlin et al., « Pulmonary Arteriovenous Malformations: Effect of Embolization on Right-to-Left Shunt, Hypoxemia, and Exercise Tolerance in 66 Patients, AJR. American Journal of Roentgenology, vol.179, issue.2, pp.347-55, 2002.

B. K. Hall, Earliest Evidence of Cartilage and Bone Development in Embryonic Life, Clinical Orthopaedics and Related Research, issue.225, pp.255-72, 1987.

A. Hosman, C. J. Westermann, R. Snijder, F. Disch, C. L. Mummery et al., « Follow-up of Thalidomide Treatment in Patients with Hereditary Haemorrhagic Telangiectasia, Rhinology, vol.53, issue.4, pp.340-384, 2015.

J. Huang, J. Elicker, N. Bowens, X. Liu, L. Cheng et al., « Myocardin Regulates BMP10 Expression and Is Required for Heart Development, The Journal of Clinical Investigation, vol.122, issue.10, pp.3678-91, 2012.

M. Humbert, R. J. Barst, I. M. Robbins, R. N. Channick, N. Galiè et al., « Combination of Bosentan with Epoprostenol in Pulmonary Arterial Hypertension: BREATHE-2 », The European Respiratory Journal, vol.24, issue.3, pp.353-59, 2004.

M. Humbert, G. Monti, F. Brenot, O. Sitbon, A. Portier et al., « Increased Interleukin-1 and Interleukin-6 Serum Concentrations in Severe Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.151, issue.5, pp.1628-1659, 1995.


M. Humbert, J. G. Coghlan, H. Ghofrani, F. Grimminger, J. He et al., Riociguat for the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Results from PATENT-1 and PATENT-2 », Annals of the Rheumatic Diseases, vol.76, issue.2, pp.422-448, 2017.

. Humbert, E. M. Marc, D. Lau, X. Montani, O. Jaïs et al., « Advances in Therapeutic Interventions for Patients with Pulmonary Arterial Hypertension, Circulation, vol.130, pp.2189-2208, 2014.

M. Humbert, N. W. Morrell, L. Stephen, K. R. Archer, M. R. Stenmark et al., « Cellular and molecular pathobiology of pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, pp.13-24

M. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield et al., « Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist, The Journal of Pharmacology and Experimental Therapeutics, vol.327, issue.3, pp.736-781, 2008.

R. Invernizzi, F. Quaglia, C. Klersy, F. Pagella, F. Ornati et al., « Efficacy and Safety of Thalidomide for the Treatment of Severe Recurrent Epistaxis in Hereditary Haemorrhagic Telangiectasia: Results of a Non-Randomised, Single-Centre, Phase 2 Study, The Lancet. Haematology, vol.2, issue.11, pp.195-202, 2015.

W. Ishida, T. Hamamoto, K. Kusanagi, K. Yagi, M. Kawabata et al., « Smad6 Is a Smad1/5-Induced Smad Inhibitor. Characterization of Bone Morphogenetic Protein-Responsive Element in the Mouse Smad6 Promoter, The Journal of Biological Chemistry, vol.275, issue.9, pp.6075-79


V. N. Iyer, R. Dinesh, B. S. Apala, A. Pannu, W. Kotecha et al., Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding, vol.93, pp.155-66, 2018.

Z. Jing, K. Parikh, T. Pulido, C. Jerjes-sanchez, R. J. White et al., « Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial ». Circulation, vol.127, issue.5, pp.624-657

D. W. Johnson, J. N. Berg, M. A. Baldwin, C. J. Gallione, I. Marondel et al., « Mutations in the Activin Receptor-like Kinase 1 Gene in Hereditary Haemorrhagic Telangiectasia Type 2 », Nature Genetics, vol.13, issue.2, pp.189-95, 1996.

T. Kameda, C. Koike, K. Saitoh, A. Kuroiwa, and H. Iba, « Developmental Patterning in Chondrocytic Cultures by Morphogenic Gradients: BMP Induces Expression of Indian Hedgehog and Noggin », Genes to Cells: Devoted to Molecular & Cellular Mechanisms, vol.4, issue.3, pp.175-84, 1999.

T. Katagiri, M. Imada, T. Yanai, T. Suda, N. Takahashi et al., « Identification of a BMP-Responsive Element in Id1, the Gene for Inhibition of Myogenesis, Genes to Cells: Devoted to Molecular & Cellular Mechanisms, vol.7, issue.9, pp.949-60, 2002.

T. Katagiri and . Et-tetsuro-watabe, Bone Morphogenetic Proteins, vol.8

E. Kessler, K. Takahara, L. Biniaminov, M. Brusel, and D. S. Greenspan, Bone Morphogenetic Protein-1: The Type I Procollagen C-Proteinase ». Science, vol.271, pp.360-62

Y. H. Kim, M. Kim, S. Choe, D. Sprecher, Y. J. Lee et al., « Selective Effects of Oral Antiangiogenic Tyrosine Kinase Inhibitors on an Animal Model of Hereditary Hemorrhagic Telangiectasia, Journal of Thrombosis and Haemostasis: JTH, vol.15, issue.6, pp.1095-1102, 2017.

M. Kiyono, M. Shibuya-;-klepfish, A. , A. Berrebi, and A. Schattner, « Intranasal Tranexamic Acid Treatment for Severe Epistaxis in Hereditary Hemorrhagic Telangiectasia, Bone Morphogenetic Protein 4 Mediates Apoptosis of Capillary Endothelial Cells during Rat Pupillary Membrane Regression, vol.23, p.767, 2001.

S. Kokabu, L. Gamer, K. Cox, J. Lowery, K. Tsuji et al., Aris Economides, Takenobu Katagiri, et Vicki Rosen. « BMP3 Suppresses Osteoblast Differentiation of Bone Marrow Stromal Cells via Interaction with Acvr2b, Molecular Endocrinology, vol.26, issue.1, pp.87-94, 2012.


O. Korchynskyi and . Peter-ten-dijke, « Identification and Functional Characterization of Distinct Critically Important Bone Morphogenetic Protein-Specific Response Elements in the Id1 Promoter, The Journal of Biological Chemistry, vol.277, issue.7, pp.4883-91

E. Kovacs-sipos, D. Holzmann, T. Scherer, M. B. Et, and . Soyka, « Nintedanib as a Novel Treatment Option in Hereditary Haemorrhagic Telangiectasia, BMJ Case Reports, 2017.

R. Kurstin, Using Thalidomide in a Patient with Epithelioid Leiomyosarcoma and Osler-Weber-Rendu Disease, Oncology, vol.16, issue.1, pp.21-24, 2002.

P. Lacroix and . Recent, Nature, vol.156, pp.576-576, 1945.

E. M. Lau, E. Giannoulatou, D. S. Celermajer, and M. Humbert, « Epidemiology and Treatment of Pulmonary Arterial Hypertension », Nature Reviews. Cardiology, vol.14, issue.10, pp.603-617, 2017.

A. Lavoisier and . De, Auteur du texte. Traité élémentaire de chimie. Tome 1 / , présenté dans un ordre nouveau, et d'après les découvertes modernes ; avec figures : par M. Lavoisier, Seconde édition, 1793, pp.1743-1794

G. Lazaraki, E. Akriviadis, I. Pilpilidis, and I. Parisi, Dimitrios Tzilves, et Anestis Tarpangos. « Low Dose of Bevacizumab Is Safe and Effective in Preventing Bleeding Episodes in Hereditary Hemorrhagic Telangiectasia, The American Journal of Gastroenterology, vol.106, issue.12, pp.2204-2210, 2011.

C. Léauté-labrèze, E. Dumas-de-la-roque, T. Hubiche, F. Boralevi, and J. Thambo, et Alain Taïeb. « Propranolol for Severe Hemangiomas of Infancy, vol.358, pp.2649-51

F. Lebrin, S. Srun, K. Raymond, and S. Martin, Stieneke van den Brink, Catarina Freitas, Christiane Bréant, et al. « Thalidomide Stimulates Vessel Maturation and Reduces Epistaxis in Individuals with Hereditary Hemorrhagic Telangiectasia », Nature Medicine, vol.16, issue.4, pp.420-448, 2010.

N. Y. Lee, C. Kellye, R. D. Kirkbride, G. C. Sheu, and . Blobe, « The Transforming Growth Factor-Beta Type III Receptor Mediates Distinct Subcellular Trafficking and Downstream Signaling of Activin-like Kinase (ALK)3 and ALK6 Receptors, Molecular Biology of the Cell, vol.20, pp.4362-70, 2009.

J. Lerut, G. Orlando, R. Adam, C. Sabbà, R. Pfitzmann et al., Liver Transplantation for Hereditary Hemorrhagic Telangiectasia: Report of the European Liver Transplant Registry, vol.244, pp.854-862, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00515733

S. Levet, D. Ciais, G. Merdzhanova, C. Mallet, T. A. Zimmers et al., BMP9) Controls Lymphatic Vessel Maturation and Valve Formation, Bone Morphogenetic Protein, vol.9, issue.4, pp.598-607

D. Y. Li, L. K. Sorensen, B. S. Brooke, L. D. Urness, E. C. Davis et al., Defective Angiogenesis in Mice Lacking Endoglin ». Science, vol.284, pp.1534-1571

. Lin, S. R. Jingmei, M. Patel, G. R. Wang, and . Dressler, « The Cysteine-Rich Domain Protein KCP Is a Suppressor of Transforming Growth Factor Beta/Activin Signaling in Renal Epithelia, Molecular and Cellular Biology, vol.26, issue.12, pp.4577-85, 2006.

. Lin, K. K. Shuxian, J. Q. Svoboda, . Feng, . Et-xinquan et al., « The Biological Function of Type I Receptors of Bone Morphogenetic Protein in Bone, Bone Research, vol.4, p.16005

D. Liu, J. Wang, B. Kinzel, M. Müeller, X. Mao et al., « Dosage-Dependent Requirement of BMP Type II Receptor for Maintenance of Vascular Integrity, Blood, vol.110, issue.5, pp.1502-1512, 2007.

. Long, M. R. Lu, T. K. Maclean, I. Jeffery, X. Morecroft et al.,

. Morrell, Serotonin Increases Susceptibility to Pulmonary Hypertension in BMPR2-Deficient Mice, Circulation Research, vol.98, issue.6, pp.818-845


T. López-rovira, E. Chalaux, J. Massagué, J. L. Rosa, F. Et et al., « Direct Binding of Smad1 and Smad4 to Two Distinct Motifs Mediates Bone Morphogenetic Protein-Specific Transcriptional Activation of Id1 Gene, The Journal of Biological Chemistry, vol.277, issue.5, pp.3176-85

J. W. Lowery, P. Et-mark, and . De-caestecker, « BMP Signaling in Vascular Development and Disease, Cytokine & Growth Factor Reviews, vol.21, issue.4, pp.287-98, 2010.

M. Lozano, Tranexamic Acid in Hereditary Hemorrhagic Telangiectasia, vol.346, p.457

A. Lupu, C. Stefanescu, X. Treton, A. Attar, O. Corcos et al., « Bevacizumab as Rescue Treatment for Severe Recurrent Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia, Journal of Clinical Gastroenterology, vol.47, issue.3, pp.256-57, 2013.

F. P. Luyten, N. S. Cunningham, S. Vukicevic, V. Paralkar, U. Ripamonti et al., « Advances in Osteogenin and Related Bone Morphogenetic Proteins in Bone Induction and Repair, Acta Orthopaedica Belgica, vol.58, issue.1, pp.263-67, 1992.

G. D. Lyons, R. E. Owens, and D. F. Mouney, « Argon Laser Destruction of Cutaneous Telangiectatic Lesions ». The Laryngoscope 91, pp.1322-1347, 1981.


K. M. Lyons, R. W. Pelton, and B. L. Hogan, « Patterns of Expression of Murine Vgr-1 and BMP-2a RNA Suggest That Transforming Growth Factor-Beta-like Genes Coordinately Regulate Aspects of Embryonic Development, Genes & Development, vol.3, issue.11, pp.1657-68, 1989.

R. Macarron, M. N. Banks, D. Bojanic, D. J. Burns, A. Dragan et al., « Impact of high-throughput screening in biomedical research », Nature Reviews Drug Discovery, vol.10, p.188

R. D. Machado, M. W. Pauciulo, J. R. Thomson, K. B. Lane, N. V. Morgan et al., « BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary Hypertension, American Journal of Human Genetics, vol.68, issue.1, pp.92-102, 2001.

J. J. Mager, T. C. Timotheus, H. Overtoom, J. W. Blauw, . Lammers et al., « Embolotherapy of Pulmonary Arteriovenous Malformations: Long-Term Results in 112 Patients, Journal of Vascular and Interventional Radiology: JVIR, vol.15, issue.5, pp.451-56, 2004.

G. Marqués, M. Musacchio, M. J. Shimell, K. Wünnenberg-stapleton, K. W. Cho et al., Production of a DPP Activity Gradient in the Early Drosophila Embryo through the Opposing Actions of the SOG and TLD Proteins, vol.91, pp.417-443

S. Mazerbourg, C. Klein, J. Roh, N. Kaivo-oja, D. G. Mottershead et al., Growth Differentiation Factor-9

, Signaling Is Mediated by the Type I Receptor, Activin Receptor-like Kinase 5, Molecular Endocrinology, vol.18, issue.3, pp.653-65, 2004.


K. A. Mcallister, K. M. Grogg, D. W. Johnson, C. J. Gallione, M. A. Baldwin et al., « Endoglin, a TGF-Beta Binding Protein of Endothelial Cells, Is the Gene for Hereditary Haemorrhagic Telangiectasia Type 1 », Nature Genetics, vol.8, issue.4, pp.345-51, 1994.

V. V. Mclaughlin, L. Raymond, L. J. Benza, R. N. Rubin, R. Channick et al., « Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension: A Randomized Controlled Clinical Trial, Journal of the American College of Cardiology, vol.55, pp.1915-1937

M. Mcmurtry, S. Sean, X. Bonnet, J. R. Wu, A. Dyck et al., « Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis, Circulation Research, vol.95, issue.8, pp.830-870


A. Mitchell, L. A. Adams, G. Macquillan, J. Tibballs, . Rohan-vanden-driesen et al., Bevacizumab Reverses Need for Liver Transplantation in Hereditary Hemorrhagic Telangiectasia ». Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol.14, pp.210-223, 2008.

K. Miyazawa, K. Et, and . Miyazono, Regulation of TGF-? Family Signaling by Inhibitory Smads, vol.9, 2017.


K. Miyazono, Y. Kamiya, M. Et, and . Morikawa, Bone Morphogenetic Protein Receptors and Signal Transduction, vol.147, pp.35-51, 2010.

M. Morikawa, D. Koinuma, K. Miyazono, and C. Heldin, « Genome-Wide Mechanisms of Smad Binding, Oncogene, vol.32, issue.13, pp.1609-1624


N. W. Morrell, X. Yang, P. D. Upton, K. B. Jourdan, N. Morgan et al., « Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells from Patients with Primary Pulmonary Hypertension to Transforming Growth Factor-Beta(1) and Bone Morphogenetic Proteins, Circulation, vol.104, issue.7, pp.790-95, 2001.

M. Moser, O. Binder, Y. Wu, J. Aitsebaomo, R. Ren et al., Antagonizes Bone Morphogenetic Protein Signaling and Endothelial Cell Differentiation ». Molecular and Cellular Biology, vol.23, issue.16, pp.5664-79, 2003.

R. Naeije and A. Manes, « The Right Ventricle in Pulmonary Arterial Hypertension, European Respiratory Review: An Official Journal of the European Respiratory Society, vol.23, issue.134, pp.476-87, 2014.

T. Nakase, S. Nomura, H. Yoshikawa, J. Hashimoto, S. Hirota et al., « Transient and Localized Expression of Bone Morphogenetic Protein 4 Messenger RNA during Fracture Healing, Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, vol.9, issue.5, pp.651-59, 1994.

M. Nasim, T. Talat, M. Ogo, R. Ahmed, . Randall et al., « Molecular Genetic Characterization of SMAD Signaling Molecules in Pulmonary Arterial Hypertension, Human Mutation, vol.32, issue.12, pp.1385-89, 2011.

S. M. Nelsen, J. L. Et, and . Christian, Site-Specific Cleavage of BMP4 by Furin, PC6, and PC7, vol.284, pp.27157-66

K. Niessen, G. Zhang, J. B. Ridgway, H. Chen, M. Et et al., ALK1 Signaling Regulates Early Postnatal Lymphatic Vessel Development, vol.115, pp.1654-61

M. Nili, U. Shinde, P. Et, and . Rotwein, « Soluble Repulsive Guidance Molecule c/Hemojuvelin Is a Broad Spectrum Bone Morphogenetic Protein (BMP) Antagonist and Inhibits Both BMP2-and BMP6-Mediated Signaling and Gene Expression, The Journal of Biological Chemistry, vol.285, pp.24783-92


H. Nishitoh, H. Ichijo, M. Kimura, T. Matsumoto, F. Makishima et al., « Identification of Type I and Type II Serine/Threonine Kinase Receptors for Growth/Differentiation Factor-5 », The Journal of Biological Chemistry, vol.271, pp.21345-52

. Nolan-stevaux, W. Olivier, S. Zhong, K. Culp, J. Shaffer et al., et Astrid Ruefli-Brasse. « Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies, vol.7, p.50920, 2012.

S. Oh, T. Paul, K. A. Seki, T. Goss, Y. Imamura et al., Activin receptor-like kinase 1 modulates transforming growth factor-?1 signaling in the regulation of angiogenesis, Proceedings of the National Academy of Sciences of the United States of America 97, vol.14, pp.2626-2657

H. Olschewski, F. Rose, E. Grünig, H. A. Ghofrani, D. Walmrath et al., Cellular Pathophysiology and Therapy of Pulmonary Hypertension, vol.138, pp.367-77, 2001.

S. L. Ondra, H. Troupp, E. D. George, and K. Schwab, « The Natural History of Symptomatic Arteriovenous Malformations of the Brain: A 24-Year Follow-up Assessment », Journal of Neurosurgery, vol.73, issue.3, pp.387-91, 1990.


D. Onichtchouk, Y. G. Chen, R. Dosch, V. Gawantka, H. Delius et al., « Silencing of TGF-Beta Signalling by the Pseudoreceptor BAMBI », Nature, vol.401, pp.480-85

S. Oosting, W. Nagengast, . Et-elisabeth-de, and . Vries, More on Bevacizumab in Hereditary Hemorrhagic Telangiectasia, vol.361, p.931

C. Otten, J. Knox, G. Boulday, M. Eymery, M. Haniszewski et al., Systematic Pharmacological Screens Uncover Novel Pathways Involved in Cerebral Cavernous Malformations, EMBO Molecular Medicine, vol.10, p.10, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02335582

M. Ouarné, C. Bouvard, G. Boneva, C. Mallet, J. Ribeiro et al., Acts as a Quiescence Factor on Tumor Growth, Vessel Normalization and Metastasis in a Mouse Model of Breast Cancer, et Sabine Bailly. « BMP9, but Not BMP10, vol.37, p.209, 2018.

E. Ozkaynak, D. C. Rueger, E. A. Drier, C. Corbett, R. J. Ridge et al., « OP-1 CDNA Encodes an Osteogenic Protein in the TGF-Beta Family, The EMBO Journal, vol.9, issue.7, pp.2085-93

E. Ozkaynak, P. N. Schnegelsberg, D. F. Jin, G. M. Clifford, F. D. Warren et al., « Osteogenic Protein-2. A New Member of the Transforming Growth Factor-Beta Superfamily Expressed Early in Embryogenesis, The Journal of Biological Chemistry, vol.267, pp.25220-25247

M. S. Parmacek, J. A. Et, and . Epstein, « Cardiomyocyte Renewal, The New England Journal of Medicine, vol.361, issue.1, pp.86-88


D. Pereira and . Williams, « Origin and evolution of high throughput screening, British journal of pharmacology, vol.152, issue.1, pp.53-61, 2007.

R. C. Pereira, A. N. Economides, and E. E. Canalis, Bone Morphogenetic Proteins Induce Gremlin, a Protein That Limits Their Activity in Osteoblasts, vol.141, pp.4558-63, 2000.

. Pérez-encinas, M. Manuel, E. Martínez, and . López, « Is Thalidomide Effective for the Treatment of Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia?, Haematologica, vol.87, issue.8, p.34, 2002.

F. Perros, S. Cohen-kaminsky, N. Gambaryan, B. Girerd, N. Raymond et al., Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease, American Journal of Respiratory and Critical Care Medicine, vol.187, issue.2, pp.189-96

S. Piccolo, E. Agius, B. Lu, S. Goodman, L. Dale et al., « Cleavage of Chordin by Xolloid Metalloprotease Suggests a Role for Proteolytic Processing in the Regulation of Spemann Organizer Activity, Cell, vol.91, issue.3, pp.80424-80433

J. S. Pollak, S. Saluja, A. Thabet, K. J. Henderson, N. Denbow et al., « Clinical and Anatomic Outcomes after Embolotherapy of Pulmonary Arteriovenous Malformations, Journal of Vascular and Interventional Radiology: JVIR, vol.17, issue.1, pp.35-44, 2006.

L. C. Price, S. J. Wort, F. Perros, P. Dorfmüller, A. Huertas et al., « Inflammation in Pulmonary Arterial Hypertension ». Chest, vol.141, issue.1, pp.210-231, 2012.

T. Pulido, I. Adzerikho, R. N. Channick, M. Delcroix, N. Galiè et al., « Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension, The New England Journal of Medicine, vol.369, issue.9, pp.809-827

S. Pushpakom, F. Iorio, P. A. Eyers, K. J. Escott, S. Hopper et al., Drug Repurposing: Progress, Challenges and Recommendations, vol.18, pp.41-58, 2019.

M. Rabinovitch, Molecular Pathogenesis of Pulmonary Arterial Hypertension, The Journal of Clinical Investigation, vol.118, issue.7, pp.2372-79, 2008.


R. C. Renaud, H. Et, and . Xuereb, « Erectile-Dysfunction Therapies », Nature Reviews. Drug Discovery, vol.1, issue.9, pp.663-64, 2002.

N. Revencu, L. M. Boon, J. B. Mulliken, O. Enjolras, M. R. Cordisco et al., Vein of Galen Aneurysmal Malformation, and Other Fast-Flow Vascular Anomalies Are Caused by RASA1 Mutations, Human Mutation, vol.29, issue.7, pp.959-65, 2008.


N. Revencu, M. Et, and . Vikkula, Cerebral Cavernous Malformation: New Molecular and Clinical Insights, vol.43, pp.716-737, 2006.

N. Ricard, D. Ciais, S. Levet, M. Subileau, C. Mallet et al., et Sabine Bailly. « BMP9 and BMP10 Are Critical for Postnatal Retinal Vascular Remodeling, vol.119, pp.6162-71

V. Rosen, J. M. Wozney, E. A. Wang, P. Cordes, A. Celeste et al., « Purification and Molecular Cloning of a Novel Group of BMPs and Localization of BMP MRNA in Developing Bone, Connective Tissue Research, vol.20, pp.313-332, 1989.

B. L. Rosenzweig, T. Imamura, T. Okadome, G. N. Cox, H. Yamashita et al., « Cloning and Characterization of a Human Type II Receptor for Bone Morphogenetic Proteins, Proceedings of the National Academy of Sciences of the United States of America, vol.92, pp.7632-7668


L. J. Rubin, B. David, R. J. Badesch, N. Barst, C. M. Galie et al., « Bosentan Therapy for Pulmonary Arterial Hypertension, The New England Journal of Medicine, vol.346, pp.896-903

L. J. Rubin, B. David, T. R. Badesch, N. Fleming, G. Galiè et al., « Long-Term Treatment with Sildenafil Citrate in Pulmonary Arterial Hypertension: The SUPER-2 Study, vol.140, pp.1274-83, 2011.

S. Ruiz, P. Chandakkar, H. Zhao, J. Papoin, K. Prodyot et al., Fabien Campagne, et Philippe Marambaud. « Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-offunction and improves HHT vascular pathology, Human Molecular Genetics, vol.26, pp.4786-98

S. Ruiz, H. Zhao, P. Chandakkar, P. K. Chatterjee, J. Papoin et al., Fabien Campagne, et Philippe Marambaud. « A Mouse Model of Hereditary Hemorrhagic Telangiectasia Generated by Transmammary-Delivered Immunoblocking of BMP9 and BMP10 », Scientific Reports, vol.5, p.37366, 2016.

S. D. Rybalkin, C. Yan, K. E. Bornfeldt, and J. A. Beavo, « Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function, Circulation Research, vol.93, issue.4, pp.280-91

C. Sabbà, M. Gallitelli, and G. Palasciano, « Efficacy of Unusually High Doses of Tranexamic Acid for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia, The New England Journal of Medicine, vol.345, p.926, 2001.

T. A. Samad, A. Rebbapragada, E. Bell, Y. Zhang, Y. Sidis et al., « DRAGON, a Bone Morphogenetic Protein Co-Receptor », The Journal of Biological Chemistry, vol.280, issue.14, pp.14122-14151

T. K. Sampath, J. E. Coughlin, R. M. Whetstone, D. Banach, C. Corbett et al., « Bovine Osteogenic Protein Is Composed of Dimers of OP-1 and BMP-2A, Two Members of the Transforming Growth Factor-Beta Superfamily, The Journal of Biological Chemistry, vol.265, pp.13198-205

K. Satoh, N. Kikuchi, T. Satoh, R. Kurosawa, S. Sunamura et al., Nobuhiro Yaoita, et Hiroaki Shimokawa. « Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension, International Journal of Molecular Sciences, vol.19, p.12, 2018.

S. Kimio, M. Tetsuya, O. Suzuki-jun, R. Michael, N. Patrizia et al., « Cyclophilin A Mediates Vascular Remodeling by Promoting Inflammation and Vascular Smooth Muscle Cell Proliferation, Circulation, vol.117, pp.3088-98

M. Scharpfenecker, M. Van-dinther, Z. Liu, R. L. Van-bezooijen, Q. Zhao et al., « BMP-9 Signals via ALK1 and Inhibits BFGF-Induced Endothelial Cell Proliferation and VEGF-Stimulated Angiogenesis », Journal of Cell Science, vol.120, pp.964-72

S. Tsugio, Y. Jihye, O. S. Et, and . Paul, « Arterial Endothelium-Specific Activin Receptor-Like Kinase 1 Expression Suggests Its Role in Arterialization and Vascular Remodeling, Circulation Research, vol.93, issue.7, pp.682-89, 2003.


E. Seront, A. Van-damme, and L. M. Boon, et Miikka Vikkula. « Rapamycin and Treatment of Venous Malformations, vol.26, p.185, 2019.

A. B. Shafritz, E. M. Shore, F. H. Gannon, M. A. Zasloff, R. Taub et al., « Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva, The New England Journal of Medicine, vol.335, issue.8, pp.555-61

A. Sharma, C. Obiagwu, K. Mezue, A. Garg, D. Mukherjee et al., « Role of Vasodilator Testing in Pulmonary Hypertension ». Emerging Trends and Current Controversies in Heart Failure, vol.58, pp.425-458

M. Shintani, H. Yagi, T. Nakayama, T. Saji, and R. Matsuoka, « A New Nonsense Mutation of SMAD8 Associated with Pulmonary Arterial Hypertension », Journal of Medical Genetics, vol.46, issue.5, pp.331-368, 2009.

C. L. Shovlin, A. E. Guttmacher, E. Buscarini, M. E. Faughnan, R. H. Hyland et al., Diagnostic Criteria for Hereditary Hemorrhagic Telangiectasia (Rendu-Osler-Weber Syndrome), vol.91, pp.66-67

C. L. Shovlin, Hereditary Haemorrhagic Telangiectasia: Pathophysiology, Diagnosis and Treatment, vol.24, pp.203-222, 2010.


C. Sieber, J. Kopf, C. Hiepen, P. Et, and . Knaus, Recent Advances in BMP Receptor Signaling, vol.20, pp.343-55, 2009.

O. Sitbon, R. Channick, K. M. Chin, A. Frey, S. Gaine et al., Selexipag for the Treatment of Pulmonary Arterial Hypertension, The New England Journal of Medicine, vol.373, pp.2522-2555

O. Sitbon, M. Delcroix, E. Bergot, A. B. Boonstra, J. Granton et al., EPITOME-2: An Open-Label Study Assessing the Transition to a New Formulation of Intravenous Epoprostenol in Patients with Pulmonary Arterial Hypertension, American Heart Journal, vol.167, issue.2, pp.210-227, 2014.

A. I. Skaro, J. Paul, V. C. Marotta, and . Mcalister, « Regression of Cutaneous and Gastrointestinal Telangiectasia with Sirolimus and Aspirin in a Patient with Hereditary Hemorrhagic Telangiectasia, Annals of Internal Medicine, vol.144, issue.3, pp.226-253

N. Sommer, Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, Pulmonary Circulation, vol.9, issue.2, pp.1-3, 2018.

. Song, J. E. Yanli, H. Jones, J. F. Beppu, J. Keaney et al., « Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice, Circulation, vol.112, issue.4, pp.553-62


. Soubrier, W. K. Florent, R. Chung, E. Machado, M. Grünig et al., Genetics and Genomics of Pulmonary Arterial Hypertension ». Journal of the American College of Cardiology, vol.62, pp.13-21

E. Spiekerkoetter, Y. K. Sung, D. Sudheendra, M. Bill, A. Micheala et al., Anton Vonk Noordegraaf, et al. « Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.192, issue.2, pp.254-57

E. Spiekerkoetter, Y. K. Sung, D. Sudheendra, V. Scott, P. D. Rosario et al., « Randomised Placebo-Controlled Safety and Tolerability Trial of FK506 (Tacrolimus) for Pulmonary Arterial Hypertension, The European Respiratory Journal, vol.50, p.3, 2017.


E. Spiekerkoetter, X. Tian, J. Cai, R. K. Hopper, D. Sudheendra et al., « FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension, The Journal of Clinical Investigation, vol.123, issue.8, pp.3600-3613

. Srinivasan, M. A. Sudha, T. Hanes, M. E. Dickens, S. P. Porteous et al., « A Mouse Model for Hereditary Hemorrhagic Telangiectasia (HHT) Type 2 », Human Molecular Genetics, vol.12, issue.5, pp.473-82

A. Stahl, K. M. Connor, P. Sapieha, J. Chen, R. J. Dennison et al., The Mouse Retina as an Angiogenesis Model ». Investigative Ophthalmology & Visual Science, vol.51, pp.2813-2839, 2010.


J. P. Stasch, E. M. Becker, C. Alonso-alija, H. Apeler, K. Dembowsky et al., « Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease, Circulation, vol.410, pp.2263-73

P. Suppressa, S. Patrizia, A. Liso, L. Arcangelo, C. Sabbà et al., « Low Dose Intravenous Bevacizumab for the Treatment of Anaemia in Hereditary Haemorrhagic Telangiectasia, British Journal of Haematology, vol.152, issue.4, p.365, 2011.

A. Suzuki, E. Kaneko, N. Ueno, and A. Hemmati-brivanlou, Regulation of Epidermal Induction by BMP2 and BMP7 Signaling, vol.189, pp.112-134

P. Dijke, H. Ten, T. K. Yamashita, A. H. Sampath, M. Reddi et al., « Identification of Type I Receptors for Osteogenic Protein-1 and Bone Morphogenetic Protein-4 », The Journal of Biological Chemistry, vol.269, pp.16985-88

M. Uebelhoer, L. M. Boon, and M. Vikkula, « Vascular Anomalies: From Genetics toward Models for Therapeutic Trials ». Cold Spring Harbor Perspectives in Medicine 2, 2012.

P. D. Upton, J. Rachel, R. C. Davies, N. W. Trembath, and . Morrell, Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells, vol.284, pp.15794-804


M. R. Urist and . Bone, Formation by Autoinduction ». Science, vol.150, pp.893-99

M. R. Urist, S. Kovacs, and K. A. Yates, « Regeneration of an Enchondroma Defect under the Influence of an Implant of Human Bone Morphogenetic Protein, The Journal of Hand Surgery, vol.11, issue.3, pp.80153-80161, 1986.

G. Valdimarsdottir, M. Goumans, A. Rosendahl, and M. Brugman, Susumu Itoh, Franck Lebrin, Paschalis Sideras, et Peter ten Dijke. « Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Protein-Induced Activation of Endothelial Cells, Circulation, vol.106, pp.2263-70

M. Vikkula, L. M. Boon, K. L. Carraway, J. T. Calvert, A. J. Diamonti et al., Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2, Cell, vol.87, issue.7, pp.1181-90

S. H. Vitali, G. Hansmann, C. Rose, A. Fernandez-gonzalez, A. Scheid et al., The Sugen 5416/Hypoxia Mouse Model of Pulmonary Hypertension Revisited: Long-Term Follow-Up ». Pulmonary Circulation, vol.4, pp.619-648, 2014.

E. A. Wang, V. Rosen, P. Cordes, R. M. Hewick, M. J. Kriz et al., « Purification and Characterization of Other Distinct Bone-Inducing Factors, Proceedings of the National Academy of Sciences, vol.85, issue.24, pp.9484-88

G. Wang, R. Fan, R. Ji, W. Zou, D. J. Penny et al., « Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report, BMC Pulmonary Medicine, vol.16


X. Wang, T. Lian, X. Jiang, S. Liu, S. Li et al., Germline BMP9 Mutation Causes Idiopathic Pulmonary Arterial Hypertension, The European Respiratory Journal, vol.53, issue.3, 2019.

R. I. White, A. Lynch-nyhan, P. Terry, P. C. Buescher, E. J. Farmlett et al., « Pulmonary Arteriovenous Malformations: Techniques and Long-Term Outcome of Embolotherapy, Radiology, vol.169, issue.3, pp.663-69, 1988.

W. L. Wooderchak-donahue, J. Mcdonald, O. Brendan, P. D. Fallon, W. Upton et al., « BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia, American Journal of Human Genetics, vol.93, pp.530-567


J. M. Wozney, V. Rosen, A. J. Celeste, L. M. Mitsock, M. J. Whitters et al., « Novel Regulators of Bone Formation: Molecular Clones and Activities, Science, vol.242, pp.1528-1562


Y. Xiao, L. Xiang, J. Et, and . Shao, Bone Morphogenetic Protein ». Biochemical and Biophysical Research Communications, vol.362, issue.3, pp.550-53

Y. Xing, S. Zhao, Q. Wei, S. Gong, X. Zhao et al., « A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels, European Respiratory Journal, vol.51, issue.4, p.1702229, 2018.

H. Xue, J. Li, H. Xie, Y. Et, and . Wang, « Review of Drug Repositioning Approaches and Resources, International Journal of Biological Sciences, vol.14, issue.10, pp.1232-1276, 2018.

N. Yamamoto, S. Akiyama, T. Katagiri, M. Namiki, T. Kurokawa et al., « Smad1 and Smad5 Act Downstream of Intracellular Signalings of BMP-2 That Inhibits Myogenic Differentiation and Induces Osteoblast Differentiation in C2C12 Myoblasts, Biochemical and Biophysical Research Communications, vol.238, issue.2, pp.574-80


. Yoshimatsu, Y. G. Yasuhiro, Y. Lee, L. Akatsu, H. I. Taguchi et al., Bone Morphogenetic Protein-9 Inhibits Lymphatic Vessel Formation via Activin Receptor-like Kinase 1 during Development and Cancer Progression, Proceedings of the National Academy of Sciences of the United States of America, vol.110, pp.18940-18985, 2013.

P. B. Yu, H. Beppu, N. Kawai, E. Li, and K. D. Bloch, « Bone Morphogenetic Protein (BMP) Type II Receptor Deletion Reveals BMP Ligand-Specific Gain of Signaling in Pulmonary Artery Smooth Muscle Cells, The Journal of Biological Chemistry, vol.280, pp.24443-50

J. X. Yuan, A. M. Aldinger, M. Juhaszova, J. Wang, J. V. Conte et al., « Dysfunctional Voltage-Gated K+ Channels in Pulmonary Artery Smooth Muscle Cells of Patients with Primary Pulmonary Hypertension, Circulation, vol.98, issue.14, pp.1400-1406

S. Yuan, Q. Pan, W. Liu, B. Wu, and X. Han, et Zhenggang Bi. « Recombinant BMP, vol.4, issue.7

, Fusion Protein Induces Differentiation of Bone Marrow Stem Cells, vol.112, pp.3054-60, 2011.

. Yurchenko, G. Vyacheslav, . Zybarth, O. Matthew, W. W. Connor et al., Active Site Residues of Cyclophilin A Are Crucial for Its Signaling Activity via CD147 », Journal of Biological Chemistry, vol.277, pp.22959-65

W. Zheng, N. Thorne, C. Et-john, and . Mckew, « Phenotypic screens as a renewed approach for drug discovery ». Drug discovery today 18, pp.1067-73, 2013.

L. Zilberberg, L. Y. Peter-ten-dijke, D. B. Sakai, and . Rifkin, « A rapid and sensitive bioassay to measure bone morphogenetic protein activity, BMC Cell Biology, vol.8, issue.1, p.41, 2007.

, Annals of Surgery, vol.10, issue.5, pp.352-68

«. , ,. _fr.pdf, and ». , , 2019.

, Origine et évolution de l'appareil respiratoire aérien des Vertébrés -EM|consulte